Bisphosphonates: Prevention of Bone Metastases in Lung Cancer
Bisphosphonates: Prevention of Bone Metastases in Lung Cancer
复制标题
DOI：
10.1007/978-3-642-21892-7_4
复制
发表时间：
2012-01-01
期刊：
影响因子：
--
通讯作者：
Nackaerts, Kristiaan
中科院分区：
文献类型：
--
作者：
Decoster, Lynn;de Marinis, Filippo;Nackaerts, Kristiaan
在肺癌患者中，骨骼是最常见的远处扩散部位之一，大约30%的患者出现骨转移。这些患者中约有一半将经历与尿道相关的事件，其发生不仅影响生活质量，而且与预后不良相关。双膦酸盐目前是治疗肺癌患者骨转移的主要药物，已证实对预防和延迟骨骼并发症具有有益作用。它们在预防骨转移发展中的作用、抗肿瘤特性及其对生存的影响仍有待阐明。其他骨靶向治疗正在II期和III期临床试验中进行研究，并可能在不久的将来扩大治疗范围。
In patients with lung cancer, bone is one of the most frequent sites of distant spread, with approximately 30% of patients developing skeletal metastases. About half of these patients will experience a skeletal-related event, the occurrence of which not only affects quality of life, but is also associated with poor prognosis. Bisphosphonates are currently the mainstay for treating bone metastases in patients with lung cancer, with proven beneficial effects on prevention and delay of skeletal complications. Their role in preventing the development of skeletal metastases, their anti-tumoral properties and their effect on survival remain to be elucidated. Other bone-targeted therapies are being investigated in phase II and III clinical trials and might expand the therapeutic arsenal in the near future.